129 related articles for article (PubMed ID: 29524408)
1. Downregulation of TXNIP leads to high proliferative activity and estrogen-dependent cell growth in breast cancer.
Park JW; Lee SH; Woo GH; Kwon HJ; Kim DY
Biochem Biophys Res Commun; 2018 Apr; 498(3):566-572. PubMed ID: 29524408
[TBL] [Abstract][Full Text] [Related]
2. Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression.
Wang C; Bai F; Zhang LH; Scott A; Li E; Pei XH
Breast Cancer Res; 2018 Jul; 20(1):74. PubMed ID: 29996906
[TBL] [Abstract][Full Text] [Related]
3. TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer.
Nie W; Huang W; Zhang W; Xu J; Song W; Wang Y; Zhu A; Luo J; Huang G; Wang Y; Guan X
Oncotarget; 2015 Feb; 6(5):3003-12. PubMed ID: 25605021
[TBL] [Abstract][Full Text] [Related]
4. Estrogen-mediated signaling is differentially affected by the expression levels of Sfrp1 in mammary epithelial cells.
Gregory KJ; Schneider SS
Cell Biol Int; 2015 Jul; 39(7):873-9. PubMed ID: 25809273
[TBL] [Abstract][Full Text] [Related]
5. TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.
Wang Y; Chen S
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34614512
[TBL] [Abstract][Full Text] [Related]
6. Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth.
Izzo F; Mercogliano F; Venturutti L; Tkach M; Inurrigarro G; Schillaci R; Cerchietti L; Elizalde PV; Proietti CJ
Breast Cancer Res; 2014 Dec; 16(6):491. PubMed ID: 25479686
[TBL] [Abstract][Full Text] [Related]
7. Aberrant expression of novel and previously described cell membrane markers in human breast cancer cell lines and tumors.
Huang H; Groth J; Sossey-Alaoui K; Hawthorn L; Beall S; Geradts J
Clin Cancer Res; 2005 Jun; 11(12):4357-64. PubMed ID: 15958618
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous mammary intraepithelial lesions in dogs--a model of breast cancer.
Antuofermo E; Miller MA; Pirino S; Xie J; Badve S; Mohammed SI
Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2247-56. PubMed ID: 17982119
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
Massarweh S; Osborne CK; Jiang S; Wakeling AE; Rimawi M; Mohsin SK; Hilsenbeck S; Schiff R
Cancer Res; 2006 Aug; 66(16):8266-73. PubMed ID: 16912207
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells.
Baldan F; Mio C; Lavarone E; Di Loreto C; Puglisi F; Damante G; Puppin C
Oncol Rep; 2015 May; 33(5):2199-206. PubMed ID: 25812606
[TBL] [Abstract][Full Text] [Related]
11. KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer.
Christgen M; Bruchhardt H; Ballmaier M; Krech T; Länger F; Kreipe H; Lehmann U
Int J Cancer; 2008 Nov; 123(10):2239-46. PubMed ID: 18712725
[TBL] [Abstract][Full Text] [Related]
12. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
13. Disturbance of Mammary UDP-Glucuronosyltransferase Represses Estrogen Metabolism and Exacerbates Experimental Breast Cancer.
Zhou X; Zheng Z; Xu C; Wang J; Min M; Zhao Y; Wang X; Gong Y; Yin J; Guo M; Guo D; Zheng J; Zhang B; Yin X
J Pharm Sci; 2017 Aug; 106(8):2152-2162. PubMed ID: 28479355
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer.
Chen Z; Yuan YC; Wang Y; Liu Z; Chan HJ; Chen S
Breast Cancer Res Treat; 2015 Jul; 152(1):29-39. PubMed ID: 26026468
[TBL] [Abstract][Full Text] [Related]
15. Genetic screening reveals an essential role of p27kip1 in restriction of breast cancer progression.
Yuan Y; Qin L; Liu D; Wu RC; Mussi P; Zhou S; Songyang Z; Xu J
Cancer Res; 2007 Sep; 67(17):8032-42. PubMed ID: 17804714
[TBL] [Abstract][Full Text] [Related]
16. Combined histone deacetylase inhibition and tamoxifen induces apoptosis in tamoxifen-resistant breast cancer models, by reversing Bcl-2 overexpression.
Raha P; Thomas S; Thurn KT; Park J; Munster PN
Breast Cancer Res; 2015 Feb; 17(1):26. PubMed ID: 25848915
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-regulated gene networks in human breast cancer cells: involvement of E2F1 in the regulation of cell proliferation.
Stender JD; Frasor J; Komm B; Chang KC; Kraus WL; Katzenellenbogen BS
Mol Endocrinol; 2007 Sep; 21(9):2112-23. PubMed ID: 17550982
[TBL] [Abstract][Full Text] [Related]
18. Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Kundu N; Brekman A; Kim JY; Xiao G; Gao C; Bargonetti J
Oncotarget; 2017 Jul; 8(29):47916-47930. PubMed ID: 28615518
[TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.
Treeck O; Lattrich C; Springwald A; Ortmann O
Breast Cancer Res Treat; 2010 Apr; 120(3):557-65. PubMed ID: 19434490
[TBL] [Abstract][Full Text] [Related]
20. RbAp46 inhibits estrogen-stimulated progression of neoplastigenic breast epithelial cells.
Zhang TF; Yu SQ; Wang ZY
Anticancer Res; 2007; 27(5A):3205-9. PubMed ID: 17970062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
